Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

AUTOR(ES)

Taylor, R S

FONTE

BMJ Publishing Group Ltd.

RESUMO

Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?

Documentos Relacionados

• US politicians want federal funding to discover cost effectiveness of new drugs
• Cost effectiveness of heart drugs varies widely, study shows
• New methods of analysing cost effectiveness
• MPs call for shake-up in how NICE reviews cost effectiveness of drugs
• Effectiveness and cost effectiveness of television, radio and print advertisements in promoting the New York smokers' quitline